Interferon beta 1b (Extavia®) – Multiple Sclerosis – as per NICE TA 527

NICE recommendations, summary of meeting discussions, links to additional supporting docs etc.

March 2002:

Funded by a DoH risk sharing scheme

April 2013: NHS England SCG took over commissioning responsibility for this treatment.

NICE TA32 (January 2002) and NHS England Policy: NHSCB/D04/P/a  (April 2013) – http://www.england.nhs.uk/wp-content/uploads/2013/04/d04-p-a.pdf

July 2018:

The TAG acknowledged NICE TA 527: Beta interferons (Avonex®, Betaferon®, Extavia®, Rebif®) and glatiramer acetate (Copaxone®) for treating multiple sclerosis, which stated:

1.1 Interferon beta 1a is recommended as an option for multiple sclerosis only if:

*           the person has relapsing-remitting multiple sclerosis and

* the companies provide it according to commercial arrangements.

1.2 Interferon beta 1b (Extavia) is recommended as an option for treating multiple sclerosis, only if:

*           the person has relapsing-remitting multiple sclerosis and has had 2 or more relapses within the last 2 years or

*           the person has secondary progressive multiple sclerosis with continuing relapses and

*           the company provides it according to the commercial arrangement.

1.3 Glatiramer acetate is recommended as an option for multiple sclerosis, only if:

*           the person has relapsing-remitting multiple sclerosis and

*           the company provides it according to the commercial arrangement.

1.4 Interferon beta 1b (Betaferon) is not recommended as an option for treating multiple sclerosis.